Loading…
NeuroPace, Inc. is projected to rise to $19.84 by 2027, a +16% move from its current price of $17.06. NPCE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $16.57 | $17.06 | $17.57 | -0.01% |
| May 30 | $16.36 | $17.06 | $17.78 | -0.01% |
| May 31 | $16.21 | $17.06 | $17.95 | -0.02% |
| Jun 1 | $16.08 | $17.06 | $18.09 | -0.03% |
| Jun 2 | $15.97 | $17.05 | $18.21 | -0.04% |
| Jun 3 | $15.87 | $17.05 | $18.32 | -0.04% |
| Jun 4 | $15.78 | $17.05 | $18.43 | -0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $15.78 | $17.05 | $18.43 | -0.05% |
| Week 2 | $15.27 | $17.04 | $19.02 | -0.10% |
| Week 3 | $14.89 | $17.03 | $19.49 | -0.15% |
| Week 4 | $14.58 | $17.03 | $19.88 | -0.20% |
| Week 5 | $14.30 | $17.02 | $20.24 | -0.26% |
| Week 6 | $14.06 | $17.01 | $20.57 | -0.31% |
| Week 7 | $13.84 | $17.00 | $20.88 | -0.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy.
Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures.
NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California. The company also provides the physician tablet used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions.
NeuroPace, Inc. (NPCE) is a Healthcare stock currently trading at $16.92. The market capitalization stands at $576.87M and the company is ranked 2934 by market cap.
The price outlook is constructive, with the forecast projecting the average price to move higher over time. The 2026 forecast shows an average of $16.92, and the trajectory climbs to $36.30 on average by 2030, continuing to $184.76 on average by 2050.
Throughout the forecast horizon, sentiment shifts from NEUTRAL in 2026 to BULLISH in subsequent years, with upside potential reflected in rising averages and escalating ROIs—culminating in an average price of $184.76 by 2050 and a forecasted ROI of 992% at that horizon.
A major floor 24.7% below — a decisive break under it would weaken the trend.
The nearest floor, 10.0% below — buyers have tended to step in here.
The nearest ceiling, 13.1% above — a clean break opens room to run.
A major ceiling 24.1% above — clearing it would confirm fresh momentum.
Key NPCE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NPCE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $16.64 | Buy | $16.68 | Buy |
| MA 10 | $16.20 | Buy | $16.53 | Buy |
| MA 20 | $16.68 | Buy | $16.45 | Buy |
| MA 50 | $15.54 | Buy | $15.94 | Buy |
| MA 100 | $15.46 | Buy | $15.31 | Buy |
| MA 200 | $13.71 | Buy | $14.25 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.48 | Neutral |
| Stoch RSI (14) | 38.13 | Neutral |
| CCI (20) | 33.70 | Neutral |
| Williams %R (14) | -56.74 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -7.03 | Sell |
| Bollinger %B (20,2) | 0.60 | Neutral |
| Stochastic %K (14) | 43.26 | Neutral |
| TRIX (15) | 0.20 | Buy |
| Awesome (5,34) | 0.24 | Buy |
| Ultimate (7,14,28) | 68.69 | Neutral |
| Momentum (10) | 1.26 | Buy |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 17.05 | Buy |
| ADX (14) | 17.00 | Neutral |
| ATR (14) | 0.43 | Info |
The 30-day technical picture is BULLISH. The RSI(14) is 60, which sits in a neutral-to-bullish zone. The 50-day simple moving average is $15.43 and the 200-day simple moving average is $13.63, indicating an upward tilt in the short-to-intermediate trend.
The 30-day range spans from $13.82 to $20.72, offering some near-term variability. Support is identified at $14.88 and resistance at $19.29, suggesting a defined trading range near current levels. Annualized volatility stands at 60%, underscoring notable price movement potential over time.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.84 | $17.06 | $22.51 | 0% | Neutral | |
| $15.62 | $19.84 | $26.77 | +16% | Neutral | |
| $20.00 | $26.16 | $36.65 | +53% | Bullish | |
| $22.72 | $30.46 | $43.97 | +79% | Bullish | |
| $25.35 | $34.74 | $51.43 | +104% | Bullish | |
| $27.77 | $38.82 | $58.77 | +128% | Bullish | |
| $27.18 | $38.72 | $59.79 | +127% | Bullish | |
| $28.88 | $41.87 | $65.83 | +145% | Bullish | |
| $34.48 | $50.85 | $81.28 | +198% | Bullish | |
| $41.60 | $62.33 | $101.18 | +265% | Bullish | |
| $53.82 | $86.80 | $150.29 | +409% | Bullish | |
| $91.55 | $167.82 | $319.13 | +884% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $12.84 | $17.06 | $19.97 | +0.00% |
| June 2026 | $14.13 | $16.62 | $20.03 | -2.58% |
| July 2026 | $14.28 | $16.95 | $20.73 | +1.97% |
| August 2026 | $14.25 | $17.04 | $21.07 | +0.52% |
| September 2026 | $13.70 | $16.47 | $20.55 | -3.30% |
| October 2026 | $13.69 | $16.55 | $20.82 | +0.48% |
| November 2026 | $14.30 | $17.37 | $22.01 | +4.95% |
| December 2026 | $14.46 | $17.65 | $22.51 | +1.60% |
Click any year to see its month-by-month NPCE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect NPCE to range from $12.84 to $22.51 through 2026. The $17.06 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The NPCE price prediction for 2027 points to an average of $19.84 (low $15.62, high $26.77) — a potential gain of +16% on today's $17.06. Price action looks broadly range-bound.
In 2028, NPCE is projected to trade between $20.00 and $36.65, averaging $26.16 — a potential gain of +53% from today's $17.06. That is up +32% on the projected 2027 average. Buyers look set to stay in control over this stretch.
NeuroPace, Inc.'s 2029 outlook centres on $30.46, within a $22.72 to $43.97 range. That is up +16% on the projected 2028 average. That marks a +79% change versus current levels. Momentum favours further upside here.
By 2030, NPCE could reach as high as $51.43, with a base case around $34.74 and support toward $25.35 — roughly +104% from $17.06. Buyers look set to stay in control over this stretch.
Expect NPCE to range from $27.77 to $58.77 through 2031. The $38.82 average target implies a +128% move from current prices. That is up +12% on the projected 2030 average. Momentum favours further upside here.
The NPCE price prediction for 2032 points to an average of $38.72 (low $27.18, high $59.79) — a potential gain of +127% on today's $17.06. Buyers look set to stay in control over this stretch.
In 2033, NPCE is projected to trade between $28.88 and $65.83, averaging $41.87 — a potential gain of +145% from today's $17.06. That is up +8% on the projected 2032 average. Momentum favours further upside here.
NeuroPace, Inc.'s 2034 outlook centres on $50.85, within a $34.48 to $81.28 range. That is up +21% on the projected 2033 average. That marks a +198% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, NPCE could reach as high as $101.18, with a base case around $62.33 and support toward $41.60 — roughly +265% from $17.06. Momentum favours further upside here.
Expect NPCE to range from $53.82 to $150.29 through 2040. The $86.80 average target implies a +409% move from current prices. That is up +39% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The NPCE price prediction for 2050 points to an average of $167.82 (low $91.55, high $319.13) — a potential gain of +884% on today's $17.06. Momentum favours further upside here.
Investing $1,000 in NPCE today (≈ 58.616647 NPCE) could be worth
$9,836.8
+$8,836.8 (+884%) by 2050 · US Dollar
Based on the average projected NPCE price of $167.82 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NPCEwould be worth at today's price.
$1,000 invested in NPCE on May 27, 2025 (≈ 78.988943 NPCE) would be worth
$1,347.55
+$347.55 (+34.8%) today · 1.35× · US Dollar
Based on a NPCE entry price of $12.66 vs. today's $17.06.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $16.27 | $1,048.56 | +4.9% |
| 1 month ago | $17.25 | $988.99 | -1.1% |
| 3 months ago | $15.02 | $1,135.82 | +13.6% |
| 6 months ago | $16.36 | $1,042.79 | +4.3% |
| 1 year ago | $12.66 | $1,347.55 | +34.8% |
| All time (5.0y) ago | $23.16 | $736.61 | -26.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NPCE forecast.
Our base-case forecast reaches $34.00 around 2030.
Implied market cap at $34.00: $1.16B
The multi-year forecast lays out a clear upside path. In 2030, the average price is $36.30 with a max of $54.30 and a min of $26.24, yielding an estimated ROI of 114.5% and a bullish outlook. The momentum continues through 2040, where the average is $95.58 and the max approaches $168.04 with an ROI of 464.9%.
By 2050, the average forecast is $184.76, the min is $98.00, the max is $357.74, and the ROI is 992 with a bullish sentiment.
Beyond the mid-term, 2027 and 2028 show solid upside (avg $20.07 and $27.11 with ROIs of 18.6 and 60.2, respectively), followed by sustained gains through 2029 (avg $31.45, ROI 85.9) and 2031–2035, where the averages continue to rise to $40.93, $40.29, $44.41, and $66.92 with substantial ROI gains. The long horizon features bullish momentum and very large upside potential, but these are estimates, not guarantees, and depend on future conditions and market dynamics. The forecast also shows high annualized volatility (60%), highlighting the risk of sharp moves alongside the upside.
Tap a question to reveal the answer.
2030: min $26.24, avg $36.30, max $54.30; ROI 114.5; sentiment BULLISH.
Forecasts show a path of rising averages with bullish sentiment from 2027 onward. The 2026 average equals $16.92, rising to $36.30 by 2030 and $184.76 by 2050, with ROI rising to 114.5% by 2030 and 992% by 2050.
Yes. The 2033 forecast sets an average of $44.41 with a max of $70.69 and a positive bullish sentiment.
The 30-day range is $13.82 to $20.72, with support at $14.88 and resistance at $19.29.
2050: min $98.00, avg $184.76, max $357.74; ROI 992; sentiment BULLISH.
NeuroPace, Inc. Community Discussion
0Share your NeuroPace, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.